Every material Form 8-K HeartBeam, Inc. has filed with the SEC since June 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HeartBeam, Inc. signed an at-the-market equity offering sales agreement with Titan Partners Securities LLC, allowing it to sell up to $25,000,000 of common stock over time through the sales agent. Sales would be made under an existing shelf registration statement and a prospectus supplement dated August 14, 2026, and the sales agent would receive a commission of up to 3% of gross sales price, which could dilute existing shareholders.
Agreement dated August 14, 2026 with Titan Partners Securities LLC as sales agent
Up to $25,000,000 of common stock, par value $0.0001 per share, may be sold from time to time
Commission of up to 3% of gross sales price per share sold through the agent
Sales would be made under Form S-3 shelf Registration No. 333-293307 and a prospectus supplement dated August 14, 2026
HeartBeam, Inc. received a Nasdaq notice on June 30, 2026, saying its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The notice has no immediate effect on the listing, but the company must regain compliance by December 28, 2026, or face possible delisting.
Nasdaq letter dated June 30, 2026 cites non-compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Company has a 180 calendar day compliance period, until December 28, 2026, to show a closing bid of at least $1.00 for ten consecutive business days
A second 180-day period may be available if the company meets market value and other initial listing standards, and the company says it cannot assure it will regain compliance
HeartBeam said CEO Robert Eno agreed to leave as CEO and board member effective June 30, 2026, as part of a strategic reorganization. Founder and President Branislav Vajdic will become principal executive officer effective July 1, 2026, and the company said it will license its 3D ECG technology to established partners rather than rely only on direct medical device sales. Shareholders face a leadership transition and a change in business model, and the filing gives no financial results for the period.
Robert Eno's departure as CEO, board member and principal executive officer is effective June 30, 2026; he is expected to enter a consulting agreement.
Branislav Vajdic, Ph.D., becomes principal executive officer effective July 1, 2026; Rich Ferrari, Executive Chairman, co-leads the implementation teams.
Mark Strome resigned from the board and all committees effective immediately, as notified on June 18, 2026.
The company will provide more details on its strategy on its Second Quarter 2026 conference call in August.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HeartBeam, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →